Compile Data Set for Download or QSAR
maximum 50k data
Found 1039 with Last Name = 'tahirovic' and Initial = 'ya'
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM50304090(CHEMBL594615 | N-(4-(3-(2-(3,4-Dichlorophenylamino...)
Affinity DataKi:  14nMAssay Description:Displacement of [3H]astemizole from human recombinant ERG expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Emory University

Curated by ChEMBL
LigandPNGBDBM50304085(CHEMBL607819 | N-(2-(3,4-Dichlorophenylamino)ethyl...)
Affinity DataKi:  119nMAssay Description:Displacement of [3H]ifenprodil form NR2B receptor in Wistar rat cerebral cortex membraneMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM50304088(CHEMBL596046 | N-(4-(2-(2-(3,4-Dichlorophenylamino...)
Affinity DataKi:  300nMAssay Description:Displacement of [3H]astemizole from human recombinant ERG expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Emory University

Curated by ChEMBL
LigandPNGBDBM50304087(CHEMBL596036 | N-(4-(2-(3-(3,4-Dichlorophenyl)-2-o...)
Affinity DataKi:  300nMAssay Description:Displacement of [3H]ifenprodil form NR2B receptor in Wistar rat cerebral cortex membraneMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168618(US9079852, Table F, Compound 3)
Affinity DataKi:  553nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Emory University

Curated by ChEMBL
LigandPNGBDBM50304086(CHEMBL594417 | N-(4-(2-(4-(3,4-Dichlorophenyl)pipe...)
Affinity DataKi:  817nMAssay Description:Displacement of [3H]ifenprodil form NR2B receptor in Wistar rat cerebral cortex membraneMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168620(US9079852, Table F, Compound 5)
Affinity DataKi:  1.00E+3nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168617(US9079852, Table F, Compound 2)
Affinity DataKi:  1.60E+3nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM50304091(CHEMBL609857 | N-(3,4-Dichlorocinnamyl)-3-(4-(meth...)
Affinity DataKi:  3.00E+3nMAssay Description:Displacement of [3H]astemizole from human recombinant ERG expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM50304089(CHEMBL595318 | N-(2-(3,4-Dichlorophenylamino)ethyl...)
Affinity DataKi:  4.62E+3nMAssay Description:Displacement of [3H]astemizole from human recombinant ERG expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168626(US9079852, Table F, Compound 11)
Affinity DataKi:  5.00E+3nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168625(US9079852, Table F, Compound 10)
Affinity DataKi:  7.50E+3nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168622(US9079852, Table F, Compound 7)
Affinity DataKi:  7.50E+3nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168621(US9079852, Table F, Compound 6)
Affinity DataKi:  7.50E+3nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168624(US9079852, Table F, Compound 9)
Affinity DataKi:  1.00E+4nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168619(US9079852, Table F, Compound 4)
Affinity DataKi:  1.30E+4nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Emory University

Curated by ChEMBL
LigandPNGBDBM168616(US9079852, Table F, Compound 1)
Affinity DataKi:  3.90E+4nMAssay Description:Compounds were evaluated for binding to the human ether-a-go-go potassium channel (hERG) expressed in HEK293 cells by displacement of 3[H]-astemizole...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221760(US9314468, Table 7, Compound 47)
Affinity DataIC50:  1nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221860(US9314468, Table 7, Compound 147)
Affinity DataIC50:  1nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50449948(CHEMBL4173977)
Affinity DataIC50:  2.90nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDF-1alpha-induced calcium release preincubated for 25 mins followed b...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50449934(CHEMBL4162609)
Affinity DataIC50:  3.60nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDF-1alpha-induced calcium release preincubated for 25 mins followed b...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50270038(CHEMBL4062223)
Affinity DataIC50:  3.70nMAssay Description:Antagonist activity at human CXCR4 in CCRF-CEM cells assessed as decrease in SDF-1alpha stimulated Ca2+ flux preincubated for 25 mins followed by SDF...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221834(US9314468, Table 7, Compound 121)
Affinity DataIC50:  4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221857(US9314468, Table 7, Compound 144)
Affinity DataIC50:  4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221796(US9314468, Table 7, Compound 83)
Affinity DataIC50:  4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50449947(CHEMBL4159234)
Affinity DataIC50:  4.5nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDF-1alpha-induced calcium release preincubated for 25 mins followed b...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221854(US9314468, Table 7, Compound 141)
Affinity DataIC50:  5nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50315305((S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-N-(4-amin...)
Affinity DataIC50:  5nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDS1alpha-induced calcium flux pretreated for 25 mins followed by SDS1...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50315305((S)-N-((1H-benzo[d]imidazol-2-yl)methyl)-N-(4-amin...)
Affinity DataIC50:  5.20nMAssay Description:Antagonist activity at CXCR4 receptor in human CCRF-CEM cells assessed as inhibition of SDF-1alpha-induced calcium release preincubated for 25 mins f...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Mus musculus)
Emory University

Curated by ChEMBL
LigandPNGBDBM50270016(CHEMBL4070320)
Affinity DataIC50:  5.5nMAssay Description:Antagonist activity at mouse CXCR4More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221864(US9314468, Table 8, Compound 2)
Affinity DataIC50:  5.5nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221865(US9314468, Table 8, Compound 3)
Affinity DataIC50:  5.60nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221863(US9314468, Table 8, Compound 1)
Affinity DataIC50:  5.70nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221866(US9314468, Table 8, Compound 4)
Affinity DataIC50:  5.80nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50443541(CHEMBL3091687)
Affinity DataIC50:  6nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDS1alpha-induced calcium flux pretreated for 25 mins followed by SDS1...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50286298(CHEMBL4171469)
Affinity DataIC50:  6nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDF1alpha-induced calcium flux pretreated for 25 mins followed by SDF1...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50449944(CHEMBL4172669)
Affinity DataIC50:  6.10nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDF-1alpha-induced calcium release preincubated for 25 mins followed b...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50443541(CHEMBL3091687)
Affinity DataIC50:  6.30nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDF-1alpha-induced calcium release preincubated for 25 mins followed b...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50443541(CHEMBL3091687)
Affinity DataIC50:  6.30nMAssay Description:Antagonist activity at human CXCR4 in CCRF-CEM cells assessed as decrease in SDF-1alpha stimulated Ca2+ flux preincubated for 25 mins followed by SDF...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50443541(CHEMBL3091687)
Affinity DataIC50:  6.30nMAssay Description:Antagonist activity at CXCR4 receptor in human CCRF-CEM cells assessed as inhibition of SDF-1alpha-induced calcium release preincubated for 25 mins f...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50286782(CHEMBL4163770)
Affinity DataIC50:  6.40nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of CXCL12-mediated calcium flux incubated for 25 mins followed by CXCL12 ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50286782(CHEMBL4163770)
Affinity DataIC50:  6.40nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of CXCL12-mediated calcium flux incubated for 25 mins followed by CXCL12 ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50443541(CHEMBL3091687)
Affinity DataIC50:  7nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of SDF1alpha-induced calcium flux pretreated for 25 mins followed by SDF1...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221808(US9314468, Table 7, Compound 95 | US9314468, Table...)
Affinity DataIC50:  7nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221867(US9314468, Table 8, Compound 5)
Affinity DataIC50:  7.30nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221868(US9314468, Table 8, Compound 6)
Affinity DataIC50:  7.70nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221869(US9314468, Table 8, Compound 7)
Affinity DataIC50:  8.10nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221870(US9314468, Table 8, Compound 8)
Affinity DataIC50:  8.30nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM50286783(CHEMBL4159607)
Affinity DataIC50:  8.60nMAssay Description:Antagonist activity at CXCR4 in human CCRF-CEM cells assessed as inhibition of CXCL12-mediated calcium flux incubated for 25 mins followed by CXCL12 ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221853(US9314468, Table 7, Compound 140)
Affinity DataIC50:  9nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1039 total ) | Next | Last >>
Jump to: